Skip to main content
SpringerLink
Log in

The State of the Art in the Development of Pseudomonas aeruginosa Vaccines

  • Chapter
Pseudomonas aeruginosa as an Opportunistic Pathogen

Part of the book series: Infectious Agents and Pathogenesis ((IAPA))

Abstract

Pseudomonas aeruginosa continues to be a leading cause of life-threatening infections among various compromised patient populations (Table I). Dramatic advances in the fields of cancer chemotherapy, bone marrow transplantation, and the care of critically ill patients has greatly increased the numbers of hospitalized individuals at high risk for acquiring a serious P. aeruginosa infection. P. aeruginosa is now the second most common bacterial nosocomial pathogen, accounting for more than 11% of all isolates reported to the Centers for Disease Control.1

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 16.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. Horan, T. C., White, J. W, Jarvis, W. R., Emori, T. G., Culver, D. H., Munn, V. E, Thornsberry, C., Olson, D. R., and Hughes, J. M., 1986, Nosocomial infection surveillance, 1984, M.M.W.R. 35:17SS–29SS.

    CAS  Google Scholar 

  2. Lechi, A., Arosio, E., Pancera, P., Anesi, P., Zannini, G., Todeschini, G., and Cetto, G., 1984, Pseudomonas septicemia. A review of 60 cases observed in a university hospital, J. Hosp. Infect. 5:29–37.

    Article  PubMed  CAS  Google Scholar 

  3. Bryan, C. S., Reynolds, K. L., and Brenner, E. R., 1983, Analysis of 1,186 episodes of gram-negative bacteremia in non-university hospitals: The effects of antimicrobial therapy, Rev. Infect. Dis. 5:629–638.

    Article  PubMed  CAS  Google Scholar 

  4. Cross, A. S., Opal, S., and Kopecko, D., 1983, Progressive increase in antibiotic resistance of gram-negative bacterial isolates. Walter Reed Hospital, 1976–1980: Specific analysis of gentamicin, tobramycin, and amikacin resistance, Arch. Intern. Med. 143:2075–2080.

    Article  PubMed  CAS  Google Scholar 

  5. Jimenez-Lucho, V. E., Saravolatz, L. D., Medeiros, A. A., and Pohlod, D., 1986, Failure of therapy in Pseudomonas endocarditis: Selection of resistant mutants, J Infect. Dis. 154:64–68.

    Article  PubMed  CAS  Google Scholar 

  6. Sanders, C. C., and Sanders, W. E., Jr., 1985, Microbial resistance to newer generation ß-lactam antibiotics: Clinical and laboratory implications, J. Infect. Dis. 151:399–406.

    Article  PubMed  CAS  Google Scholar 

  7. Foord, R. D., Butcher, M. E., and Williams, A. H., 1987, The emergence of resistance of Pseudomonas aeruginosa in patients treated with ceftazidine, Shand J. Infect. Dis. 19:143.

    Article  CAS  Google Scholar 

  8. Cryz, S. J., Jr., 1984, Pseudomonas aeruginosa infections, in: Bacterial vaccines, (R. Germanier, ed.), Academic Press, Orlando, FL, pp. 317–351.

    Chapter  Google Scholar 

  9. Young, L. S., and Armstrong, D., 1972, Human immunity to Pseudomonas aeruginosa. I. Invitro interaction of bacteria, polymorphonuclear leukocytes, and serum factors, J. Infect. Dis. 126:257–276.

    Article  PubMed  CAS  Google Scholar 

  10. Cryz, S. J., Jr., Pitt, T. L., Hirer, E., and Germanier, R., 1984, Role of lipopolysaccharide in virulence of Pseudomonas aeruginosa, Infect. Immun. 44:508–513.

    PubMed  CAS  Google Scholar 

  11. Pollack, M. S., and Young, L. S., 1979, Protective activity of antibodies to exotoxin A and lipopolysaccharide at the onset of Pseudomonas aeruginosa septicemia in man, J. Clin. Invest. 63:276–286.

    Article  PubMed  CAS  Google Scholar 

  12. Cross, A. S., Sadoff, J. C., Iglewski, B. H., and Sokol, P. A., 1980, Evidence for the role of toxin A in the pathogenesis of infection with Pseudomonas aeruginosa in humans, J. Infect. Dis. 142:538–546.

    Article  PubMed  CAS  Google Scholar 

  13. Alexander, J. W., and Fisher, M. W., 1974, Immunization against Pseudomonas in infection after thermal injury,,. Infect. Dis. 130:S152–S158.

    Article  Google Scholar 

  14. Jones, R. J., Rowe, E. A., and Gupta, J. L., 1980, Controlled trial of Pseudomonas immunoglobulin and vaccine in burn patients, Lancet 1:1263–1265.

    Article  Google Scholar 

  15. Young, L. S., Meyer, R.. D., and Armstrong, D., 1973, Pseudomonas aeruginosa vaccine in cancer patients, Ann. Intern. Med. 79:518–527.

    PubMed  CAS  Google Scholar 

  16. Haghbin, M., Armstrong, D., and Murphy, M. L., 1973, Controlled prospective trial of Pseudomonas aeruginosa vaccine in children with acute leukemia, Cancer 32:761–766.

    Article  PubMed  CAS  Google Scholar 

  17. Pennington, J. E., 1974, Preliminary investigations of Pseudomonas aeruginosa vaccine in patients with leukemia and cystic fibrosis,J. Infect. Dis. 130:S159–S162.

    Article  PubMed  Google Scholar 

  18. Polk, H. C., Jr., Borden, S., and Aldrete, J. A., 1973, Prevention of Pseudomonas respiratory infection in a surgical intensive care unit, Ann. Surg. 177:607–615.

    PubMed  Google Scholar 

  19. Langford, D. T., and Hiller, J., 1984, Prospective, controlled study of a polyvalent Pseudomonas vaccine in cystic fibrosis—three year results, Arch. Dis. Child. 59:1131–1134.

    Article  PubMed  CAS  Google Scholar 

  20. Pier, G. B., Saunders, J. M.., Ames, P., Edwards, M. S., Auerlach, H.., Goldfarb J., Speert, D. P., and Hurrvitch, S., 1987, Opsonophagocytic killing antibody to Pseudomonas aeruginosa mucoid exopolysaccharide in older noncolonized patients with cystic fibrosis, N. Engl. J. Med. 317:793–798.

    Article  PubMed  CAS  Google Scholar 

  21. Maki, D. B., 1989, Risk factors for nosocomial infection in intensive care: “Devices vs nature” and goals for the next decade, Arch. Intern. Med. 149:30–35.

    Article  PubMed  CAS  Google Scholar 

  22. Holder, I. A., and Neely, A. N., 1987, Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: Passive intravenous immunotherapy using Pseudomonas immunoglobulins, Serodiag. Immunother. 1:153–162.

    Article  Google Scholar 

  23. Lieberman, M. M., 1989, Pseudomonas aeruginosa ribosomal vaccine. A comparison of the immunogenicity of vaccines from two different serotypes, in: Pseudomonas aeruginosa Infection,Antibiotics Chemotherapy Vol. 42 (N. Hoiby, S. S. Pederson, G. H. Shand, G. Döring, and I. A. Holder, eds.), Karger, Basel, Switzerland, pp. 193–203.

    Google Scholar 

  24. Rotering, H., and Dorner, E., 1989, Studies on a Pseudomonas aeruginosa flagella vaccine, in: Pseudomonas aeruginosa Infection, Antibiotics Chemotherapy Vol. 42 (N. Hoiby, S. S. Pederson, G. H. Shand, G. Döring, and I. A. Holder, eds.), Karger, Basel, Switzerland, pp. 218–228.

    Google Scholar 

  25. Pier, G. B., and Bennett, S. E., 1986, Structural analysis and immunogenicity of Pseudomonas aeruginosa immunotype 2 high molecular weight polysaccharide, J Clin. Invest. 77:491–495.

    Article  PubMed  CAS  Google Scholar 

  26. Pier, G. B., 1982, Safety and immunogenicity of high molecular weight polysaccharide vaccine from immunotype 1 Pseudomonas aeruginosa, J. Clin. Invest. 69:303–308.

    Article  PubMed  CAS  Google Scholar 

  27. Pier, G. B., Matthews, W. J., and Eardly, D. D., 1983, Immunochemical characterization of the mucoid exopolysaccharide of Pseudomonas aeruginosa,J. Infect. Dis. 147:494–503.

    Article  PubMed  CAS  Google Scholar 

  28. Ames, P., DesJardins, D., and G. B. Pier, 1985, Opsonophagocytic killing activity of rabbit antibody to Pseudomonas aeruginosa mucoid exoploysaccharide, Infect. Immun. 49:281–285.

    PubMed  CAS  Google Scholar 

  29. Pier, G. B., 1989, Immunologic properties of Pseudomonas aeruginosa mucoid exopolysaccharide (alginate), in: Pseudomonas aeruginosa Infection,Antibiotics Chemotherapy Vol. 42 (N. Hoiby, S. S. Pederson, G. H. Shand, G. Döring, and I. A. Holder, eds.), Karger, Basel, Switzerland, pp. 80–87.

    Google Scholar 

  30. Cryz, S. J., Jr., Lang, A. B., Sadoff, J. C., Germanier, R., and Fürer, E., 1987, Vaccine potential of Pseudomonas aeruginosa O-polysaccharide-toxin A conjugates, Infect. Immun. 55:1547–1551.

    PubMed  CAS  Google Scholar 

  31. Cryz, S. J., Jr., Fürer, E., Cross, A. S., Wegmann, A., Germanier, R., and Sadoff, J. C., 1987, Safety and immunogenicity of Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine in humans, J. Clin. Invest. 80:51–56.

    Article  PubMed  CAS  Google Scholar 

  32. Cryz, S. J., Jr., Sadoff, J. C., Cross, A. S., and Fürer, E., 1989, Safety and immunogenicity of a polyvalent Pseudomonas aeruginosa O-polysaccharide-toxin A vaccine in humans, in: Pseudomonas aeruginosa Infection, Antibiotics Chemotherapy Vol. 42 (N. Hoiby, S. S. Pederson, G. H. Shand, G. Döring, and I. A. Holder, eds.), Karger, Basel, Switzerland, pp. 177–183.

    Google Scholar 

  33. Schaad, V. B., Lang, A. B., Wedgwood, J., Ruedeberg, A., Que, J. U., Fürer, E., and Cryz, S. J., Jr., Society and immunogenicity of Pseudomonas aeruginosa conjugate vaccine in cystie fibrosis, Lancet 338:1236–1237.

    Google Scholar 

  34. Gottlieb, D. J., Cryz, S. J., Jr., Fürer, E., Que, J. U., Prentice, H. G., Duncombe, A. S., and Brenner, M. K., 1990, Immunity against Pseudomonas aeruginosa adaptively transferred to bone marrow transplant recipients, Blood 76:2470–2475.

    PubMed  CAS  Google Scholar 

  35. Collins, M. S., Edwards, A., Robey, R. E., Mehton, N. S., and Ladehoff, D., 1989, Pseudomonas immune globulin therapy improves survival in experimental Pseudomonas aeruginosa bacteremic pneumonia, in: Pseudomonas aeruginosa Infection, Antibiotics Chemotherapy Vol. 42 (N. Hoiby, S. S. Pederson, G. H. Shand, G. Döring, and I. A. Holder, eds.), Karger, Basel, Switzerland, pp.184–192.

    Google Scholar 

  36. Stuttman, R., Petrovici, V., and Hartert, M., 1987, Prophylactic Pseudomonas immunoglobulin in burn patients, Infection 15:S71–S74.

    Article  Google Scholar 

  37. Böhm, D., 1987, Clinical experience in a surgical intensive care unit with a Pseudomonas immunoglobulin in ventilated patients suffering from Pseudomonas pneumonia, Infection 15: S64–S66.

    Article  PubMed  Google Scholar 

  38. Class, I., Junginger, W, and Klöss, T., 1987, Pseudomonas immunoglobulin in surgical intensive care patients on mechanical ventilation, Infection 15:567-S70.

    Article  Google Scholar 

  39. Granström, M., Wretlind, B., Markham, B., and Cryz, S. J., Jr., 1988, Enzyme-linked immunosorbent assay to evaluate the immunogenicity of a polyvalent Klebsiella capsular polysaccharide vaccine in humans, J. Clin. Microbiol. 26:2257–2261.

    PubMed  Google Scholar 

  40. Sawada, S., Kawamura, T., and Masuhq, Y., 1987, Immunoprotective human monoclonal antibodies against five major serotypes of Pseudomonas aeruginosa, J Gen. Microbiol. 133: 3581–3590.

    PubMed  CAS  Google Scholar 

  41. Zweerink, H. J., Gammon, M. C., Hutchinson, C. E, Jackson, J.J., Lombardo, D., Miner, K. M., Puckett, J. M., Sewell, T. J., and Sigal, N. H., 1988, Human monoclonal antibodies that protect mice against challenge with Pseudomonas aeruginosa,Infect. Immun. 56:1873–1879.

    PubMed  CAS  Google Scholar 

  42. Lang, A. B., Fürer, E., Senyk, G., Larrick, J. W, and Cryz, S. J., Jr., 1990, Systemic generation of antigen specific human monoclonal antibodies with therapeutic activities using active immunization, Hum. Antibodies Hybridomas 1:96–103.

    PubMed  CAS  Google Scholar 

  43. Lang, A. B., Bruderer, U., Fürer, E., Larrick, J. W, and Cryz, S. J., Jr., 1990, Immunoprotective capacities of human murine monoclonal antibodies recognizing serotype specific and common determinants of gram-negative bacteria, in: Therapeutic Monoclonal Antibodies (C. A. K. Borrebaeck and J. W. Larrick, eds.), Stockton Press, New York, pp.223–234

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Swiss Serum and Vaccine Institute, CH-3001, Berne, Switzerland

    Stanley J. Cryz Jr.

Authors
  1. Stanley J. Cryz Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Pisa, Pisa, Italy

    Mario Campa  & Mauro Bendinelli  & 

  2. University of South Florida, Tampa, Florida, USA

    Herman Friedman

Rights and permissions

Reprints and permissions

Copyright information

© 1993 Springer Science+Business Media New York

About this chapter

Cite this chapter

Cryz, S.J. (1993). The State of the Art in the Development of Pseudomonas aeruginosa Vaccines. In: Campa, M., Bendinelli, M., Friedman, H. (eds) Pseudomonas aeruginosa as an Opportunistic Pathogen. Infectious Agents and Pathogenesis. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3036-7_18

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-3036-7_18

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-6324-8

  • Online ISBN: 978-1-4615-3036-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation